About PTB domain-containing engulfment adapter protein 1
PTB domain-containing engulfment adapter protein 1 (GULP1) is a protein
from Homo sapiens identified by UniProt accession
Q9UBP9, 304 residues long.
MolForge cross-references it against 0 known binders and
66 disease associations.
Target properties
| Protein name | PTB domain-containing engulfment adapter protein 1 |
|---|
| UniProt accession | Q9UBP9 |
|---|
| Gene | GULP1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 304 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (66)
Diseases linked to this target (Open Targets).
- self reported educational attainment · score 0.41
- hemoglobin A1 measurement · score 0.30
- mathematical ability · score 0.29
- appendicular lean mass · score 0.20
- white matter microstructure measurement · score 0.10
- pulse pressure measurement · score 0.10
- vital capacity · score 0.07
- neoplasm · score 0.05
- urinary bladder carcinoma · score 0.04
- chronic obstructive pulmonary disease · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UBP9-F1 | alphafold | PREDICTED | 74.36 | — |
Amino-acid sequence (304 residues)
MNRAFSRKKD KTWMHTPEAL SKHFIPYNAK FLGSTEVEQP KGTEVVRDAV RKLKFARHIK KSEGQKIPKV ELQISIYGVK ILEPKTKEVQ HNCQLHRISF CADDKTDKRI FTFICKDSES NKHLCYVFDS EKCAEEITLT IGQAFDLAYR KFLESGGKDV ETRKQIAGLQ KRIQDLETEN MELKNKVQDL ENQLRITQVS APPAGSMTPK SPSTDIFDMI PFSPISHQSS MPTRNGTQPP PVPSRSTEIK RDLFGAEPFD PFNCGAADFP PDIQSKLDEM QEGFKMGLTL EGTVFCLDPL DSRC
Explore PTB domain-containing engulfment adapter protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets